Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 13,147,090	$ 33,794,672
Receivable due from collaboration agreement	1,812,975	1,628,703
Research and development tax incentive receivable	949,168	966,646
Prepaid assets and other current assets	1,069,761	2,447,930
Total current assets	16,978,994	38,837,951
Operating lease right-of-use asset, net	214,264
Property and equipment, net	3,026,466	1,859,860
Other assets	7,688
Total assets	20,227,412	40,697,811
Current liabilities:
Accounts payable	1,634,024	1,493,842
Accrued compensation		416,910
Deferred research grant revenue	362,710	50,000
Current portion of operating lease liability	79,838
Total current liabilities	2,076,572	1,960,752
Operating lease liability, net of current portion	128,314
Total liabilities	2,204,886	1,960,752
Commitments and contingencies (see Note 4)
Stockholders’ equity:
Common stock; $0.001 par value, 45,000,000 shares authorized; 25,518,084 and 25,371,781 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	25,518	25,372
Additional paid-in capital	107,922,543	104,078,968
Accumulated other comprehensive loss	(210,347)	(48,921)
Accumulated deficit	(89,715,188)	(65,318,360)
Total stockholders’ equity	18,022,526	38,737,059
Total liabilities and stockholders’ equity	$ 20,227,412	$ 40,697,811